Literature DB >> 18022972

Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.

Jana Kasparkova1, Marie Vojtiskova, Giovanni Natile, Viktor Brabec.   

Abstract

The different antitumor and other biological effects of the third-generation antitumor platinum drug oxaliplatin [(1R,2R-diamminocyclohexane)oxalatoplatinum(II)] in comparison with those of conventional cisplatin [cis-diamminedichloridoplatinum(II)] are often explained by the ability of oxaliplatin to form DNA adducts of different conformation and consequently to exhibit different cytotoxic effects. This work describes, for the first time, the structural and biochemical characteristics of the interstrand cross-links of oxaliplatin. We find that: 1) DNA bending, unwinding, thermal destabilization, and delocalization of the conformational alteration induced by the cross-link of oxaliplatin are greater than those observed with the cross-link of cisplatin; 2) the affinity of high-mobility-group proteins (which are known to mediate the antitumor activity of platinum complexes) for the interstrand cross-links of oxaliplatin is markedly lower than for those of cisplatin; and 3) the chirality at the carrier 1,2-diaminocyclohexane ligand can affect some important structural properties of the interstrand cross-links of cisplatin analogues. Thus, the information contained in the present work is also useful for a better understanding of how the stereochemistry of the carrier amine ligands of cisplatin analogues can modulate their anticancer and mutagenic properties. The significance of this study is also reinforced by the fact that, in general, interstrand cross-links formed by various compounds of biological significance result in greater cytotoxicity than is expected for monofunctional adducts or other intrastrand DNA lesions. Therefore, we suggest that the unique properties of the interstrand cross-links of oxaliplatin are at least partly responsible for this drug's unique antitumor effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18022972     DOI: 10.1002/chem.200701352

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  14 in total

1.  Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator.

Authors:  Johnny Moretto; Bruno Chauffert; François Ghiringhelli; Janice R Aldrich-Wright; Florence Bouyer
Journal:  Invest New Drugs       Date:  2010-06-10       Impact factor: 3.850

2.  Effect of in vivo post-translational modifications of the HMGB1 protein upon binding to platinated DNA: a molecular simulation study.

Authors:  Wenping Lyu Lv; Fabio Arnesano; Paolo Carloni; Giovanni Natile; Giulia Rossetti
Journal:  Nucleic Acids Res       Date:  2018-12-14       Impact factor: 16.971

3.  Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.

Authors:  Michael Groessl; Yury O Tsybin; Christian G Hartinger; Bernhard K Keppler; Paul J Dyson
Journal:  J Biol Inorg Chem       Date:  2010-03-07       Impact factor: 3.358

4.  Novel role of base excision repair in mediating cisplatin cytotoxicity.

Authors:  Anbarasi Kothandapani; Venkata Srinivas Mohan Nimai Dangeti; Ashley R Brown; Lauren A Banze; Xiao-Hong Wang; Robert W Sobol; Steve M Patrick
Journal:  J Biol Chem       Date:  2011-02-28       Impact factor: 5.157

5.  The stability of DNA intrastrand cross-links of antitumor transplatin derivative containing non-bulky methylamine ligands.

Authors:  Michaela Frybortova; Olga Novakova; Viktor Brabec
Journal:  J Biol Inorg Chem       Date:  2014-07-02       Impact factor: 3.358

6.  The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex.

Authors:  Eman Alaaeldin; Amr S Abu Lila; Naoto Moriyoshi; Hatem A Sarhan; Tatsuhiro Ishida; Khaled A Khaled; Hiroshi Kiwada
Journal:  Pharm Res       Date:  2013-05-15       Impact factor: 4.200

Review 7.  Platinum Complexes in Colorectal Cancer and Other Solid Tumors.

Authors:  Beate Köberle; Sarah Schoch
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

8.  DNA-Destabilizing Agents as an Alternative Approach for Targeting DNA: Mechanisms of Action and Cellular Consequences.

Authors:  Gaëlle Lenglet; Marie-Hélène David-Cordonnier
Journal:  J Nucleic Acids       Date:  2010-07-25

Review 9.  Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts.

Authors:  Gaëlle Savreux-Lenglet; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Int J Mol Sci       Date:  2015-11-05       Impact factor: 5.923

Review 10.  Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity.

Authors:  Alessia Chiorazzi; Sara Semperboni; Paola Marmiroli
Journal:  Toxics       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.